Trials / Sponsors / Krystal Biotech, Inc.
Krystal Biotech, Inc.
Industry · 17 registered clinical trials — 8 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis Neurotrophic Keratitis | Phase 1 / Phase 2 | 2025-07-07 |
| Recruiting | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | 2025-06-20 |
| Active Not Recruiting | A Study Assessing KB304 for the Treatment of Wrinkles in Women Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles | Phase 1 / Phase 2 | 2024-11-20 |
| Recruiting | A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans | — | 2024-08-02 |
| Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult | Phase 1 / Phase 2 | 2024-04-17 |
| Recruiting | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency Alpha 1-Antitrypsin Deficiency | Phase 1 | 2024-02-15 |
| Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Cancer, Melanoma Stage III, Melanoma Stage IV | Phase 1 / Phase 2 | 2023-10-31 |
| Recruiting | A Study Assessing KB407 for the Treatment of Cystic Fibrosis Cystic Fibrosis | Phase 1 | 2023-06-30 |
| Unknown | Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) Autosomal Recessive Ichthyosis | Phase 2 | 2023-03-01 |
| Withdrawn | A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis Cystic Fibrosis | Phase 1 | 2022-03-08 |
| Recruiting | Long-Term Follow-up Protocol Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | — | 2021-05-25 |
| Completed | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | 2021-05-25 |
| Active Not Recruiting | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen Skin Roughness, Wrinkle, Fine Lines | Phase 1 | 2020-10-07 |
| Completed | Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | Phase 3 | 2020-08-17 |
| Withdrawn | The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | — | 2020-01-01 |
| Unknown | Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI TGM-1 Related Autosomal Recessive Congenital Ichthyosis | Phase 1 / Phase 2 | 2019-08-27 |
| Completed | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | 2018-05-06 |